Publisher
Springer Science and Business Media LLC
Reference14 articles.
1. European Medicines Agency. Osilodrostat (Isturisa®): summary of product characteristics. 2020. https://ec.europa.eu/. Accessed 20 Jan 2020.
2. Armani S, Ting L, Sauter N, et al. Drug interaction potential of osilodrostat (LCI699) based on its effect on the pharmacokinetics of probe drugs of cytochrome P450 enzymes in healthy adults. Clin Drug Investig. 2017;37(5):465–72.
3. Fleseriu M, Pivonello R, Young J, et al. Osilodrostat, a potent oral 11beta-hydroxylase inhibitor: 22-week, prospective, phase II study in Cushing’s disease. Pituitary. 2016;19(2):138–48.
4. Recordati, Novartis P. Recordati: acquisition of worldwide rights to Signifor® and osilodrostat (LCI699) completed [media release]. 23 Oct 2019. http://www.recordati.com.
5. Recordati. Recordati to acquire worldwide rights to Signifor® and osilodrostat (LCI699) [media release]. 12 Jul 2019. http://www.recordati.com.
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献